Development and Advanced Validation of an Optimized Method for the Quantitation of Aβ42 in Human Cerebrospinal Fluid
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 3
Abstract
The online version of this article (doi:10.1208/s12248-012-9360-7) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Valerie C. Cullen, Ross A. Fredenburg, Cindy Evans, Phyllis R. Conliffe, Michael E. Solomon
Keywords
Related Articles
- EP ID EP681237
- DOI 10.1208/s12248-012-9360-7
- Views 71
- Downloads 0
Determination of carryover and contamination for mass spectrometry-based chromatographic assays
The Third American Association of Pharmaceutical Scientists/Food and Drug Administration Bioanalytical Workshop, held in 2006, reviewed and evaluated current practices and proposed that carryover and contamination be ass...
Pulmonary Immunization Using Antigen 85-B Polymeric Microparticles to Boost Tuberculosis Immunity
This study aims to evaluate immunization with polymeric microparticles containing recombinant antigen 85B (rAg85B) delivered directly to the lungs to protect against tuberculosis. rAg85B was expressed in Escherichia coli...
Effect of Device Design on the Aerosolization of a Carrier-Based Dry Powder Inhaler—a Case Study on Aerolizer® Foradile®
The objective of this study is to investigate the effect of device design of the Aerolizer® on the aerosolization of a carrier-based dry powder inhaler formulation (Foradile®). The Aerolizer was modified...
Analyzing the Cryptome: Uncovering Secret Sequences
The mammalian cryptome consists of bioactive peptides generated by the proteolysis of precursor proteins. It is speculated that the cryptide repertoire increases the complexity of the proteome by an order of magnitude. C...
Model-Based Decision Making in Early Clinical Development: Minimizing the Impact of a Blood Pressure Adverse Event
We describe how modeling and simulation guided program decisions following a randomized placebo-controlled single-rising oral dose first-in-man trial of compound A where an undesired transient blood pressure (BP) elevati...